Exudative macular degeneration and intravitreal triamcinolone. A pilot study

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Exudative age-related macular degeneration (AMD) with subfoveal or juxtafoveal choroidal new vessels presents a challenge, especially when laser photocoagulation is not an option.
• Visual acuity (VA) in these patients often deteriorates without effective treatment.

Purpose of the Study:

• To evaluate the efficacy of triamcinolone (Kenacort A-40) as an anti-inflammatory agent for treating exudative AMD.
• To assess outcomes in patients with choroidal new vessels unsuitable for conventional laser treatment.

Main Methods:

• Thirty eyes from 28 patients with exudative AMD received intravitreal injections of triamcinolone.
• Visual acuity outcomes were compared to historical data from untreated eyes.
• Patients were categorized based on their response to treatment.

Main Results:

• A significant decrease in exudation and improvement in vision were observed in 87% of patients (Types I and II) within two weeks.
• This positive trend in visual acuity persisted during extended follow-up.
• Treated eyes demonstrated significantly better VA outcomes compared to untreated eyes with similar macular lesions.

Conclusions:

• Preliminary findings suggest triamcinolone is a potentially effective treatment for exudative AMD, with no serious side effects noted after single injections in up to 18 months.
• Further research in prospective, case-controlled clinical trials is warranted to confirm efficacy and establish its role in managing this condition.